TESARO has forged several successful licensing agreements with OPKO Health, Amgen, Merck, and AnaptysBio

License Agreement with OPKO Health

In December 2010, TESARO and OPKO Health signed a definitive agreement granting TESARO exclusive rights for the development, manufacture, commercialization and distribution of rolapitant and a related compound. The terms of this agreement included an up-front payment to OPKO and additional potential payments based upon achievement of specified regulatory and commercialization milestones, in addition to double digit tiered-royalties on sales. TESARO and OPKO will share future profits from the commercialization of licensed products in Japan and OPKO will have an option to market the products in Latin America. In addition, OPKO acquired a 10% equity position in TESARO.

TESARO is responsible for all clinical, regulatory and other activities necessary to develop and commercialize rolapitant. At the time of the license transaction, rolapitant had completed Phase 2 clinical trials for prevention of chemotherapy-induced nasusea and vomiting and was ready to begin Phase 3.
Read the full press release

License Agreement with Amgen

In March 2011, TESARO signed an agreement with Amgen Inc. for exclusive worldwide rights for the development, manufacture, commercialization and distribution of small molecule inhibitors of Anaplastic Lymphoma Kinase (ALK). The agreement included an upfront payment and potential future payments and royalties associated with the achievement of certain development and commercial milestones.

TESARO was responsible for all clinical, regulatory and other activities necessary for development and commercialization. At the time of the license transaction, these molecules were in preclinical development.
Read the full press release

License Agreement with Merck

In May 2012, TESARO entered into a license agreement with Merck Sharp & Dohme Corp., a subsidiary of Merck, under which we obtained exclusive, worldwide rights to certain patents and non-exclusive rights to certain Merck know-how, to research, develop, manufacture, market and sell niraparib and a backup compound, MK-2512, for all therapeutic and prophylactic uses in humans. This agreement was structured to include an up-front payment to Merck of in connection with initiation of the license agreement, in addition payments for achievement of certain development, regulatory and sales objective milestones and royalties based on worldwide annual net sales.

TESARO is responsible for all clinical, regulatory and other activities necessary to develop and commercialize niraparib. At the time of the license transaction, niraparib had completed a Phase 1 clinical trial in cancer patients as a monotherapy.
Read the SEC filling

License Agreement with Anaptysbio

In March 2014, TESARO entered into a license agreement with AnaptysBio by which we obtained exclusive, worldwide rights to monospecific antibody drug candidates targeting TIM-3, LAG-3 and PD-1 and dual reactive antibody drug candidates targeting PD-1/TIM-3 and PD-1/LAG-3. Therapeutic antibodies selected from these programs will form the basis of a strategic platform that will enable TESARO to develop novel monotherapy and combination-based approaches with immuno-oncology and other anti-cancer agents in a variety of indications.

This agreement was structured to include an up-front payment to AnaptysBio in connection with initiation of the license agreement, in addition to milestone payments for achievement of certain development, regulatory and sales objectives and royalties based on worldwide annual net sales. AnaptysBio and TESARO will together complete preclinical development of the antibody candidates, with TESARO being solely responsible for all clinical development, manufacturing, regulatory and commercial activities.
Read the full press release